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Abstract 
 
This paper first discusses the role that new biotechnology-related firms (NBFs) are 
expected to play in the development of biotechnology-related industries and, then, 
discusses current situations surrounding NBFs in Japan based on the survey study and 
interviews we conducted with 65 NBFs.  A special emphasis is placed on the difficulties 
that NBFs face, their interaction with universities, and the role government policies can 
play on them.  As regards difficulties in starting new enterprises, many respondents 
raised difficulties in recruiting qualified researchers and in funding.  In Japan, most 
qualified researchers belong to universities and big companies and their mobility is low, 
which makes recruiting by new firms difficult.  As regards funding, many respondents 
expressed their hope that the government expands R&D-related subsidiaries.  It is 
noteworthy that they supported not just quantitative expansion, that is, an increase in 
the amount of subsidiaries, but also improvement in the ease in using subsidiaries, such 
as the flexibility in the use of money and less red tape.  The study therefore suggests 
that Japan needs a more mobile market for scientists, a more developed venture-capital 
market, and more flexible government policies in order to promote the activities of 
NBFs. 
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